This study will recruit 17 CRC patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. AB-165 (Sotevtamab) a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin. The gene discussed is CLU; the disease is cancer.